1 Dalakas MC. Stiff person syndrome: advances in pathogenesis and therapeutic interventions. Curr Treat Options Neurol. 2009;11(2):102–10.
2 McKeon A, Robinson MT, McEvoy KM, Matsumoto JY, Lennon VA, Ahlskog JE, et al. Stiff-man syndrome and variants: clinical course, treatments, and outcomes. Arch Neurol. 2012;69(2):230–8.
3 Grant R, Graus F. Paraneoplastic movement disorders. Movement Disorders. 2009;24(12):1715–24.
4 Kanaji N, Watanabe N, Kita N, Bandoh S, Tadokoro A, Ishii T, et al. Paraneoplastic syndromes associated with lung cancer. World J Clin Oncol. 2014;5(3):197–223.
5 Spiro SG, Gould MK, Colice GL. Initial evaluation of the patient with lung cancer: symptoms, signs, laboratory tests, and paraneoplastic syndromes: ACCP evidenced-based clinical practice guidelines. Chest. 2007;132(3 Suppl):07–1358.
6 Dumansky YV, Syniachenko OV, Stepko PA, Yehudina YD, Stoliarova OY. Paraneoplastic syndrome in lung cancer. Exp Oncol. 2018;40(3):239–42.
7 Poplawska-Domaszewicz K, Florczak-Wyspianska J, Kozubski W, Michalak S. Paraneoplastic movement disorders. Rev Neurosci. (Review). 2018;29(7):745–55.
8 Honnorat J, Antoine JC. Paraneoplastic neurological syndromes. Orphanet J Rare Dis. 2007;2(22):1750–172.
9 Paraschiv B, Diaconu CC, Toma CL, Bogdan MA. Paraneoplastic syndromes: the way to an early diagnosis of lung cancer. Pneumologia. 2015;64(2):14–9.
10 Moersch FP, Woltman HW. Progressive fluctuating muscular rigidity and spasm («stiff-man» syndrome); report of a case and some observations in 13 other cases. Proc Staff Meet Mayo Clin. 1956;31(15):421–7.
11 Shaw PJ. Stiff-man syndrome and its variants. Lancet. 1999;353(9147):86–7.
12 Murinson BB, Butler M, Marfurt K, Gleason S, De Camilli P, Solimena M. Markedly elevated GAD antibodies in SPS: effects of age and illness duration. Neurology. 2004;63(11):2146–8.
13 Rakocevic G, Floeter MK. Autoimmune stiff person syndrome and related myelopathies: understanding of electrophysiological and immunological processes. Muscle Nerve. 2012;45(5):623–34.
14 Walikonis JE, Lennon VA. Radioimmunoassay for glutamic acid decarboxylase (GAD65) autoantibodies as a diagnostic aid for stiff-man syndrome and a correlate of susceptibility to type 1 diabetes mellitus. Mayo Clin Proc. 1998;73(12):1161–6.
15 Dalakas MC, Li M, Fujii M, Jacobowitz DM. Stiff person syndrome: quantification, specificity, and intrathecal synthesis of GAD65 antibodies. Neurology. 2001;57(5):780–4.
16 Manto MU, Laute MA, Aguera M, Rogemond V, Pandolfo M, Honnorat J. Effects of anti-glutamic acid decarboxylase antibodies associated with neurological diseases. Ann Neurol. 2007;61(6):544–51.
17 Grimaldi LM, Martino G, Braghi S, Quattrini A, Furlan R, Bosi E, et al. Heterogeneity of autoantibodies in stiff-man syndrome. Ann Neurol. 1993;34(1):57–64.
18 Pittock SJ, Lucchinetti CF, Parisi JE, Benarroch EE, Mokri B, Stephan CL, et al. Amphiphysin autoimmunity: paraneoplastic accompaniments. Ann Neurol. 2005;58(1):96–107.
19 Murinson BB, Vincent A. Stiff-person syndrome: autoimmunity and the central nervous system. CNS Spectr. 2001;6(5):427–33.
20 Levy LM, Dalakas MC, Floeter MK. The stiff-person syndrome: an autoimmune disorder affecting neurotransmission of gamma-aminobutyric acid. Ann Intern Med. 1999;131(7):522–30.
21 Alexopoulos H, Dalakas MC. A critical update on the immunopathogenesis of Stiff Person Syndrome. Eur J Clin Invest. 2010;40(11):1018–25.
22 Dalmau J, Rosenfeld MR. Paraneoplastic syndromes of the CNS. Lancet Neurol. 2008;7(4):327–40.
23 Choii G, Ko J. Gephyrin: a central GABAergic synapse organizer. Experimental &Amp; Molecular Medicine. 2015;47:e158.
24 Griffin CE, 3rd, Kaye AM, Bueno FR, Kaye AD. Benzodiazepine pharmacology and central nervous system-mediated effects. The Ochsner journal. 2013 Summer;13(2):214–23.